SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-009133
Filing Date
2023-05-10
Accepted
2023-05-10 16:30:40
Documents
47
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20230331x10q.htm   iXBRL 10-Q 771145
2 EX-31.1 tmb-20230331xex31d1.htm EX-31.1 16125
3 EX-31.2 tmb-20230331xex31d2.htm EX-31.2 15502
4 EX-32.1 tmb-20230331xex32d1.htm EX-32.1 8281
5 EX-32.2 tmb-20230331xex32d2.htm EX-32.2 8212
  Complete submission text file 0001558370-23-009133.txt   3196470

Data Files

Seq Description Document Type Size
6 EX-101.SCH tmb-20230331.xsd EX-101.SCH 22908
7 EX-101.CAL tmb-20230331_cal.xml EX-101.CAL 16395
8 EX-101.DEF tmb-20230331_def.xml EX-101.DEF 113015
9 EX-101.LAB tmb-20230331_lab.xml EX-101.LAB 237895
10 EX-101.PRE tmb-20230331_pre.xml EX-101.PRE 191665
41 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20230331x10q_htm.xml XML 397482
Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Filer) CIK: 0001875558 (see all company filings)

IRS No.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41264 | Film No.: 23906997
SIC: 2834 Pharmaceutical Preparations